Robert D. Cardiff, MD, PhD

Robert D. Cardiff, MD, PhD

Position Title
Distinguished Professor Emeritus

Center for Comparative Medicine
SOM: Pathology and Laboratory Medicine


Research Interests: Comparative Pathology, Comparative Oncology, Informatics

Mutant Mouse Pathology Laboratory 

Dr. Cardiff continues his support of CCM’s MMP laboratory by providing interpretation of their comprehensive histopathology services to over 200 investigators in over 200 laboratories in 21 countries.  The archive includes blocks and slides from over 20,000 cases representing 200 types of genetically engineered mice, and is a unique research and training resource that is unparalleled in the world. The comparative studies have provided unique insights into the molecular and functional genomics of cancer.  The comparison of structure and function has led to the recognition that genetically engineered mice have unique forms of cancer.  Each gene produces a characteristic, and frequently unique, type of cancer.  Many of these cancers closely resemble human cancers.  Cancers of the breast, white blood cells, skin, lung, salivary gland, prostate, bone, liver, and mesenchyme have been studied. Studies done in this facility with collaborators have resulted in over 200 papers since 1990.

Recent publications:

1.            Mori H, Cardiff RD, Borowsky AD. Aging Mouse Models Reveal Complex Tumor-Microenvironment Interactions in Cancer Progression. Front Cell Dev Biol. 2018;6:35.

2.            Gattelli A, Garcia Sola ME, Roloff TC, Cardiff RD, Kordon EC, Chodosh LA, et al. Chronic expression of wild-type Ret receptor in the mammary gland induces luminal tumors that are sensitive to Ret inhibition. Oncogene. 2018;37(29):4046-54.

3.            Cardiff RD, Jindal S, Treuting PM, Going JJ, Gusterson BA, Thompson HJ. Comparative anatomy and histology : a mouse, rat, and human atlas. Second edition. ed. London: Elsevier/Academic Press; 2018. p. xviii, 487-509.

4.            Aeffner F, Adissu HA, Boyle MC, Cardiff RD, Hagendorn E, Hoenerhoff MJ, et al. Digital Microscopy, Image Analysis, and Virtual Slide Repository. ILAR J. 2018.

5.            Tung B, Schade B, Cardiff RD, Aina OH, Sanguin-Gendreau V, Muller WJ. beta-Catenin haploinsufficiency promotes mammary tumorigenesis in an ErbB2-positive basal breast cancer model. Proc Natl Acad Sci U S A. 2017;114(5):E707-E16.

6.            Mori H, Chen JQ, Cardiff RD, Penzvalto Z, Hubbard NE, Schuetter L, et al. Pathobiology of the 129:Stat1 -/- mouse model of human age-related ER-positive breast cancer with an immune infiltrate-excluded phenotype. Breast Cancer Res. 2017;19(1):102.

7.            Turpin J, Ling C, Crosby EJ, Hartman ZC, Simond AM, Chodosh LA, et al. The ErbB2DeltaEx16 splice variant is a major oncogenic driver in breast cancer that promotes a pro-metastatic tumor microenvironment. Oncogene. 2016.

8.            Schmitz J, Schwab J, Schwenck J, Chen Q, Quintanilla-Martinez L, Hahn M, et al. Decoding intratumoral heterogeneity of breast cancer by multiparametric in vivo imaging: A translational study. Cancer Res. 2016.

9.            Mori H, Cardiff RD. Methods of Immunohistochemistry and Immunofluorescence: Converting Invisible to Visible. Methods Mol Biol. 2016;1458:1-12.

10.          Adams CJ, Yu JS, Mao JH, Jen KY, Costes SV, Wade M, et al. The Trp53 delta proline (Trp53DeltaP) mouse exhibits increased genome instability and susceptibility to radiation-induced, but not spontaneous, tumor development. Mol Carcinog. 2016;55(9):1387-96.